Amendments to the Claim

Please amend claims 1, 4 and 42, as follows. Please cancel claims 50-56. Please add claims 57-60.

Listing of Claims

1. **(Currently Amended)** An isolated glycoprotein comprising the human amino acid primary structure of CD55 and a tumor-specific N-linked glycostructure, wherein said glycoprotein is isolated from a membrane preparation of gastric adenocarcinoma cells by chromatographic processes and has an apparent molecular weight of about 82 kD in sodium dodecyl sulfate polyacrylamide gel electrophoresis and is a glycoprotein present on adenocarcinoma cell line 23132 (DSMZ Accession No. DSM ACC 201), but not on a normal cell.

2-3. (Canceled).

4. **(Currently Amended)** A process for obtaining a glycoprotein comprising the human amino acid primary structure of CD55 and a tumor-specific N-linked glycostructure ~~according to claim 1~~, the process comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by size exclusion chromatography, wherein the glycoprotein has an apparent molecular weight of about 82 kD in sodium dodecyl sulfate polyacrylamide gel electrophoresis, and is a glycoprotein present on adenocarcinoma cell line 23132 (DSMZ Accession No. DSM ACC 201), but not on a normal cell.

5-41. (Canceled).

42. **(Currently Amended)** A process for obtaining a glycoprotein comprising the human amino acid primary structure of CD55 and a tumor-specific N-linked glycostructure ~~according to claim 1~~, the process comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by anion-exchange chromatography, wherein the glycoprotein has an apparent molecular weight of about 82 kD in sodium dodecyl sulfate polyacrylamide gel electrophoresis and is a glycoprotein present on adenocarcinoma cell line 23132 (DSMZ Accession No. DSM ACC 201), but not on a normal cell.

43. **(Previously Presented)** The isolated glycoprotein of claim 1, wherein said glycoprotein, if present on a cell and bound by an antibody that is specific for said glycostructure, results in apoptosis of said cell.

44. **(Canceled)**

45. **(Previously Presented)** The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in cleavage of cytokeratin 18 in said cell.

46. **(Previously Presented)** The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in increased c-myc expression in said cell.

47. **(Previously Presented)** The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in decreased topoisomerase IIα expression in said cell.

48. **(Previously Presented)** The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in an increase in intracellular Ca^{2+} concentration in said cell.

49. **(Previously Presented)** The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure does not induce cleavage of poly(ADP-ribose)-polymerase in said cell.

50-56. (Canceled)

57. **(New)** The isolated glycoprotein of claim 1, wherein said chromatographic processes are size-exclusion and/or anion-exchange chromatography.

58. **(New)** The isolated glycoprotein of claim 1, wherein said gastric adenocarcinoma cells are from the adenocarcinoma cell line 23132 (DSMZ Accession No. DSM ACC 201).

59. **(New)** An isolated glycoprotein comprising the human amino acid primary structure of CD55 and a tumor-specific N-linked glycostructure obtained by the process of claim 4.

60. **(New)** An isolated glycoprotein comprising the human amino acid primary structure of CD55 and a tumor-specific N-linked glycostructure obtained by the process of claim 42.